BMC Pulmonary Medicine (Apr 2021)

Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

  • Toshihiro Masuda,
  • Eiji Nakatani,
  • Toshihiro Shirai,
  • Taisuke Akamatsu,
  • Kanami Tamura,
  • Shingo Takahashi,
  • Yuko Tanaka,
  • Hirofumi Watanabe,
  • Yoshinari Endo,
  • Takahito Suzuki,
  • Mika Saigusa,
  • Akito Yamamoto,
  • Satoru Morita,
  • Yoko Sato,
  • Kazuhiro Asada

DOI
https://doi.org/10.1186/s12890-021-01491-w
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in preventing pneumococcal pneumonia has been controversial. Methods To evaluate the effectiveness of the PPSV23 in elderly outpatients with chronic respiratory diseases, we carried out a case–control study, including 4128 outpatients aged ≥ 65 years, in the respiratory department. Results There were 320 vaccinated patients, of which 164 were diagnosed with pneumococcal pneumonia. The adjusted odds ratio was 0.39 (95% confidence interval (CI), 0.17 to 0.89). In the subsets consisting of age groups ≥ 70 and ≥ 75 years, the adjusted odds ratio (95% CI) was respectively 0.16 (0.04 to 0.67) and 0.15 (0.02 to 1.12). Conclusion This real-world study suggests that PPSV23 can be useful in preventing pneumococcal pneumonia in the elderly with chronic respiratory diseases.

Keywords